nach oben

Erschienen in:

01.06.2014 | Original Research

⁹⁰Y Glass Microspheres for the Treatment of Unresectable Metastatic Liver Disease from Chemotherapy-Refractory Gastrointestinal Cancers: A Pilot Study

verfasst von: Nicholas Fidelman, Robert K. Kerlan Jr, Randall A. Hawkins, Andrew G. Taylor, Maureen P. Kohi, K. Pallav Kolli, Emily K. Bergsland, R. Kate Kelley, Andrew H. Ko, W. Michael Korn, Ryan M. McWhirter, Jennifer Luan, Alan P. Venook

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This prospective pilot single-institution study was undertaken to document the feasibility, safety, and efficacy of treatment of liver-dominant metastatic gastrointestinal cancer using ⁹⁰Y glass microspheres.

Methods

Between June 2010 and November 2012, 30 adult patients (22 men, eight women; median age 61 years) with metastatic chemotherapy-refractory unresectable colorectal (n = 15), neuroendocrine (n = 9), intrahepatic cholangiocarcinoma (n = 3), pancreas (n = 2), and esophageal (n = 1) carcinomas underwent 45 lobar or segmental administrations of ⁹⁰Y glass microspheres. Data regarding clinical and laboratory adverse events (AE) were collected prospectively for 6 months after each treatment. Radiographic responses were evaluated using Response Evaluation Criteria in Solid Tumors, version 1.1. Time to maximum response, response duration, progression-free survival (hepatic and extrahepatic), and overall survival were measured.

Results

Median target dose and activity were 111.6 Gy and 2.5 GBq per treatment session, respectively. All but three clinical AE were grade 1 or 2 in severity. Serious AE included an unplanned hospital admission for carcinoid crisis, grade 3 vomiting, and grade 4 gastric ulcer. Patients with colorectal cancer had hepatic objective response rate (ORR) of 27 % and a disease control rate (DCR) of 73 %. Median progression-free and overall survival were 1.0 and 4.9 months, respectively. Patients with neuroendocrine tumors had hepatic ORR and DCR of 78 % and 100 %, respectively. Median progression-free survival was 18.5 months for this cohort.

Conclusions

Y glass microspheres device has a favorable safety profile and achieved prolonged disease control of hepatic tumor burden in a subset of patients, including all patients enrolled in the neuroendocrine cohort.

Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg. 2007;11:1057–77.PubMedCrossRef

Al-Asfoor A, Feorowicz Z, Lodge M. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. Cochrane Database Syst Rev. 2008;16, CD006039. doi:10.1002/14651858.CD006039.pub4.

Llovet JM. Treatment of hepatocellular cancer. Curr Treat Options Gastroenterol. 2004;7:431–41.PubMedCrossRef

Zeissman HA, Thrall JH, Gyves JW, Ensminger WD, Niederhuber JE, Tuscan M, et al. Quantitative hepatic arterial perfusion scintigraphy and starch microspheres in cancer chemotherapy. J Nucl Med. 1983;24:871–5.

King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113:921–9. doi:10.1002/cncr.23685.PubMedCrossRef

Jakobs TF, Hoffmann RT, Dehm K, Trumm C, Stemmler HJ, Tatsch K, et al. Hepatic Yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol. 2008;19:1187–95. doi:10.1016/j.jvir.2008.05.013.PubMedCrossRef

Jakobs TF, Hoffmann RT, Fischer T, Stemmler HJ, Tatsch K, La Fougere C, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol. 2008;19:683–90. doi:10.1016/j.jvir.2008.01.009.PubMedCrossRef

Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, et al. Unresectable chemorefractory liver metastases: radioembolization with ⁹⁰Y microspheres—safety, efficacy, and survival. Radiology. 2008;247:507–15. doi:10.1148/radiol.2472062029.PubMedCrossRef

Rhee TK, Lewandowski RJ, Liu DM, Mulcahy MF, Takahashi G, Hansen PD, et al. ⁹⁰Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008;247:1029–35. doi:10.1097/SLA.0b013e3181728a45.PubMedCrossRef

10.

Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman Jr DE, Loehr SP, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65:412–25.PubMedCrossRef

11.

Nace GW, Steel JL, Amesur N, Zajko A, Nastasi BE, Joyce J, et al. Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int J Surg Oncol. 2011. doi:10.1155/2011/571261.PubMedCentralPubMed

12.

Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Ymicrospheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271–9. doi:10.1097/COC.0b013e31815e4557.PubMedCrossRef

13.

Bangash AK, Atassi B, Kaklamani V, Rhee TK, Yu M, Lewandowski RJ, et al. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol. 2007;18:621–8.PubMedCrossRef

14.

Kennedy AS, Nutting C, Jakobs T, Cianni R, Notarianni E, Ofer A, et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Investig. 2009;27:682–90. doi:10.1080/07357900802620893.CrossRef

15.

Gonsalves CF, Eschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR. 2011;196:468–73. doi:10.2214/AJR.10.4881.PubMedCrossRef

16.

Klingenstein A, Haug AR, Zech CJ, Schaller UC. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. Cardiovasc Intervent Radiol. 2013;36:158–65. doi:10.1007/s00270-012-0373-5.PubMedCrossRef

17.

Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, et al. Treatment of unresectable cholangiocarcinoma using Yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113:2119–28. doi:10.1002/cncr.23818.PubMedCrossRef

18.

Saxena A, Bester L, Chua TC, Chu FC. Morris DL (2010) Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. 2010;17:484–91. doi:10.1245/s10434-009-0777-x.PubMedCrossRef

19.

Hoffmann RT, Paprottka PM, Schon A, Bamberg F, Haug A, Durr EM, et al. Trnasarterial hepatic Yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012;35:105–16. doi:10.1007/s00270-011-0142-x.PubMedCrossRef

20.

Mouli S, Memon K, Baker T, Benson 3rd AB, Mulcahy MF, Gupta R, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24:1227–34. doi:10.1016/j.jvir.2013.02.031.PubMedCrossRef

21.

Rafi S, Piduru SM, El-Rayes B, Kauh JS, Kooby DA, Sarmiento JM, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol. 2013;36:440–8. doi:10.1007/s00270-012-0463-4.PubMedCrossRef

22.

Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy-refractory colorectal liver metastases. Br J Cancer. 2010;103:324–31. doi:10.1038/sj.bjc.6605770.PubMedCentralPubMedCrossRef

23.

Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28:3687–94. doi:10.1200/JCO.2010.28.5643.PubMedCrossRef

24.

Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek Jr AA, Kulik L, et al. Radioembolization with ⁹⁰Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571–92.PubMedCrossRef

25.

Abdelmaksoud MHK, Louie JD, Kothary N, Hwang GL, Kuo WT, Hofmann LV, et al. Consolidation of hepatic arterial inflow by embolization of variant hepatic arteries in preparation for Yttrium-90 radioembolization. J Vasc Interv Radiol. 2011;22:1364–71. doi:10.1016/j.jvir.2011.06.014.PubMedCrossRef

26.

Salem R, Thurston KG. Radioembolization with ⁹⁰Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. J Vasc Interv Radiol. 2006;17:1251–78.PubMedCrossRef

27.

Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist. 2008;13 suppl 2:19–21. doi:10.1634/theoncologist.13-S2-19.PubMedCrossRef

28.

Carter RE, Woolson RF. Statistical design considerations for pilot studies transitioning therapies from the bench to the bedside. J Transl Med. 2004;2:37–41.PubMedCentralPubMedCrossRef

29.

Winkler RL, Smith JE, Fryback DG. The role of informative priors in zero-numerator problems: being conservative versus being candid. Am Stat. 2002;56:1–4.CrossRef

30.

Memon K, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Sato KT, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys. 2012;83:887–94. doi:10.1016/j.ijrobp.2011.07.041.PubMedCentralPubMedCrossRef

31.

Hilgard P, Hamami M, Fouly AE, Scherag A, Muller S, Ertle J, et al. Radioembolization with Yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52:1741–9. doi:10.1002/hep.23944.PubMedCrossRef

32.

Lewis MA, Jaramillo S, Roberts L, Fleming CJ, Rubin J, Grothey A. Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. Oncologist. 2012;17:725–31. doi:10.1634/theoncologist.2011-0372.PubMedCentralPubMedCrossRef

33.

Ahuja C, Chadha M, Critchfield JJ. Intraoperative carcinoid hypertensive crisis precipitated by Yttrium-90 microsphere radioembolotherapy. Endocr Pract. 2010;16:1074–5.PubMed

34.

Castillo JG, Filsoufi F, Adams DH, Raikhelkar J, Zaku B, Fischer GW. Management of patients undergoing multivalvular surgery for carcinoid heart disease: the role of the anaesthetist. Br J Anaesth. 2008;101:618–26. doi:10.1093/bja/aen237.PubMedCrossRef

35.

Cao CQ, Yan TD, Bester L, Liauw W, Morris DL. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg. 2010;97:537–43. doi:10.1002/bjs.6931.PubMedCrossRef

36.

Paprottka PM, Hoffmann RT, Haug A, Sommer WH, Raessler F, Trumm CG, et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using Yttrium-90 microspheres. Cardiovasc Intervent Radiol. 2012;35:334–42. doi:10.1007/s00270-011-0248-1.PubMedCrossRef

Titel: 90Y Glass Microspheres for the Treatment of Unresectable Metastatic Liver Disease from Chemotherapy-Refractory Gastrointestinal Cancers: A Pilot Study
verfasst von: Nicholas Fidelman
Robert K. Kerlan Jr
Randall A. Hawkins
Andrew G. Taylor
Maureen P. Kohi
K. Pallav Kolli
Emily K. Bergsland
R. Kate Kelley
Andrew H. Ko
W. Michael Korn
Ryan M. McWhirter
Jennifer Luan
Alan P. Venook
Publikationsdatum: 01.06.2014
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 2/2014
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-013-9566-7

Springer Medizin

⁹⁰Y Glass Microspheres for the Treatment of Unresectable Metastatic Liver Disease from Chemotherapy-Refractory Gastrointestinal Cancers: A Pilot Study